visus.com
Provided by Alexa ranking, visus.com has ranked N/A in N/A and 9847879th on the world. It is hoted in N/A with IP address 185.215.156.237. The home page has 0 external link.
SiteTOP Score: 43804
SiteTOP Rank: 609106
Top keyword related from Search Engine of visus.com
Traffic Ranks of visus.com
Owner: |
N/A |
RANK: |
9847879 |
Country code: |
N/A |
Country name: |
N/A |
Top URL related to visus.com
-
1. Home - Visus Therapeutics™
Link: https://www.visustx.com/
Description: LEARN MORE. Visus Therapeutics, Inc.2 Nickerson St. Ste 101Seattle, WA 98109. Visus Therapeutics™ is a clinical-stage company developing innovative medicines to improve vision for people around the world.
DA: 6 PA: 88 MOZ Rank: 20
-
2. About Us - Visus Therapeutics™
Link: https://www.visustx.com/about-visus
Description: Visus Therapeutics is a team of industry leaders with vast eye care experience and an unmatched track record in the development and commercialization of innovative eye care pharmaceuticals. The breadth and depth of our collective knowledge and experience allows us to set our sights on the future of eye health, united by the common goal of ...
DA: 85 PA: 72 MOZ Rank: 82
-
3. Pipeline - Visus Therapeutics™
Link: https://www.visustx.com/pipeline
Description: PIPELINE. Our seasoned team of scientists have dedicated their lives’ work to the discovery and development of sight-preserving treatments. In some cases, this means spotlighting new applications for established therapies. In other areas, we’re developing new molecules and medicines to potentially change the standard of care for preventable ...
DA: 29 PA: 53 MOZ Rank: 29
-
4. Visus Therapeutics Announces Positive Topline Clinical Data
Link: https://www.businesswire.com/news/home/20230419006081/en/Visus-Therapeutics-Announces-Positive-Topline-Clinical-Data-from-Phase-3-Pivotal-BRIO-I-Trial-of-BRIMOCHOL-PF%E2%84%A2-for-the-Treatment-of-Presbyopia
Description: Apr 20, 2023 · Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL PF™ for the Treatment of Presbyopia | Business Wire.
DA: 77 PA: 51 MOZ Rank: 59
-
5. Visus Therapeutics, Inc. | LinkedIn
Link: https://www.linkedin.com/company/visus-therapeutics
Description: Visus Therapeutics, Inc. | 5,190 followers on LinkedIn. Our Mission: dramatically improving patients' lives by developing differentiated, best-in-class ophthalmic therapies. | With offices in ...
DA: 97 PA: 58 MOZ Rank: 14
-
6. Visus Therapeutics Expands Ophthalmic Drug Portfolio With
Link: https://www.businesswire.com/news/home/20210819005250/en/Visus-Therapeutics-Expands-Ophthalmic-Drug-Portfolio-With-Investigational-Therapies-for-Glaucoma-and-Age-related-Macular-Degeneration-Secures-Exclusive-License-for-Novel-Ophthalmic-Drug-Delivery-Technology
Description: Aug 19, 2021 · Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and Age-related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery ...
DA: 16 PA: 65 MOZ Rank: 93
-
7. Visus Therapeutics Announces $36 Million Series A Financing to …
Link: https://www.businesswire.com/news/home/20210309005270/en/Visus-Therapeutics-Announces-36-Million-Series-A-Financing-to-Advance-Development-of-Novel-Presbyopia-Correcting-Eye-Drop
Description: Mar 9, 2021 · Release Summary. Visus Therapeutics announces a $36 million Series A financing round to advance the development of BRIMOCHOL, its novel presbyopia-correcting eye drop.
DA: 79 PA: 45 MOZ Rank: 44
-
8. Visus Therapeutics Initiates Phase 3 Pivotal Trials of ... - Eyewire+
Link: https://eyewire.news/news/visus-therapeutics-initiates-phase-3-pivotal-trials-of-brimochol-pf-for-the-treatment-of-presbyopia
Description: Mar 18, 2024 · Source: Visus Therapeutics. Visus Therapeutics announced the launch of the first of two pivotal phase 3 trials (BRIO-I and BRIO-II) for its lead asset, Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia.
DA: 42 PA: 21 MOZ Rank: 4
-
9. Visus Therapeutics CEO announces acquisition of ViewPoint …
Link: https://www.ophthalmologytimes.com/view/visus-therapeutics-ceo-announces-acquisition-of-viewpoint-therapeutics-to-expand-on-cataract-presbyopia-candidate
Description: Sep 30, 2022 · Ben Bergo, CEO of Visus Therapeutics, announced the acquisition of all patents and other assets of ViewPoint Therapeutics, which will accelerate development of novel alpha-crystallin chaperone compounds as a non-surgical treatment for age-related cataracts.
DA: 41 PA: 7 MOZ Rank: 61
-
10. News - Visus Therapeutics™
Link: https://www.visustx.com/news
Description: Mar 9, 2021 · Visus in the limelight. As an active clinical-stage pharmaceutical company on the leading-edge of ophthalmic innovations, we’re bound to be making headlines. Check back often for the very latest updates, announcements, and breakthroughs that are propelling us forward.
DA: 65 PA: 44 MOZ Rank: 17